Programmable cells
Commercial scalingCells are engineered as production systems, sensors, and therapeutics.
Design-build-test loops are increasingly automated.
Industry detail
Synthetic Biology
The field now depends on automation, synthesis throughput, biosecurity, and scale-up discipline.
Scaling
Connected record
Follow the industry graph in layers
Start with the system view, then open participants, progress signals, or source records only when needed.
Industry system
Connected view
Dependencies, demand, capabilities, companies, milestones, and evidence in one workspace.
Select a node to update the detail panel.
Stage
Scaling
Companies
7
Milestones
3
Enabling stack
Global axes
Demand and adjacent markets
No records in this sample.
Core capabilities
Capability map
What has to work
The main technical capabilities that define progress in this industry.
DNA synthesis
Commercial scalingLower-cost synthesis expands what can be designed and screened.
Throughput and screening controls are now industry infrastructure.
Biomanufacturing scale-up
Pilot deploymentsFermentation and downstream processing determine unit economics.
More programs are reaching contract manufacturing and end markets.
Biosecurity screening
Pilot deploymentsScreening tools reduce misuse risk as design access broadens.
Standards bodies and vendors are aligning on screening workflows.